Skip to main content
Clinical Trials/NCT03852849
NCT03852849
Unknown
Not Applicable

Cohort Study on Appropriate Strategies of The Rapid Build of HIV Related Protective Barriers in Yunnan, China

National Center for AIDS/STD Control and Prevention, China CDC2 sites in 1 country600 target enrollmentMarch 1, 2019

Overview

Phase
Not Applicable
Intervention
The dosage of 400mg EFV
Conditions
Viral Suppression of HIV Infection
Sponsor
National Center for AIDS/STD Control and Prevention, China CDC
Enrollment
600
Locations
2
Primary Endpoint
Viral suppression of HIV-infected patients
Last Updated
7 years ago

Overview

Brief Summary

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Detailed Description

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy. This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated. The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy. Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Registry
clinicaltrials.gov
Start Date
March 1, 2019
End Date
March 1, 2021
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Center for AIDS/STD Control and Prevention, China CDC
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • HIV-positive participants who received an newly diagnosed HIV infection within the study period
  • Having a current residential address inside of pilot site limits
  • Eighteen years old or above
  • HIV transmission is heterosexual contact

Exclusion Criteria

  • Having severe mental disorder

Arms & Interventions

medicine intervention group

The dosage of 400 mg EFV will be used in the antiviral therapy.

Intervention: The dosage of 400mg EFV

consolidated intervention group

Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.

Intervention: Personal involved intervention strategies

consolidated intervention group

Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.

Intervention: The dosage of 400mg EFV

Outcomes

Primary Outcomes

Viral suppression of HIV-infected patients

Time Frame: 12 months

Secondary Outcomes

  • Treatment coverage(12 months)

Study Sites (2)

Loading locations...

Similar Trials